Outlook Therapeutics terminates May 13, 2026 prospectus supplement for ATM offering agreement with H.C. Wainwright

OTLK•2026-08-12

SEC filing update

Outlook Therapeutics Inc. (OTLK.O) said it terminates the May 13, 2026 prospectus supplement for its at-the-market offering agreement with H.C. Wainwright, according to an SEC filing.

Further company coverage: OTLK.O

Outlook Therapeutics terminates May 13, 2026 prospectus supplement for ATM offering agreement with H.C. Wainwright

SEC filing update

Related News

Biodesix 10% owner Jack W. Schuler reports $669,537 common share purchase

WEC Energy director Ulice Payne Jr sells 980 common shares worth $103,468.4

H.B. Fuller receives unsolicited USD 1.1 billion-USD 1.2 billion offer for Building Adhesive Solutions unit

Ultrapar declares BRL 1.09 billion interim dividend at BRL 1 per share

Fossil Q2 2026 results benefit from full-price selling, lifting gross margin to 62.4% company says